HK Stock Market Move | LEADS BIOLABS-B(09887) rose more than 3%, and the groundbreaking data of LBL-034 will be presented in a verbal report at the 2025 ASH Annual Meeting.

LEADS BIOLABS-B (09887) rose more than 3%, as of the press release, it had risen 2.39% to HK$53.6, with a trading volume of HK$51.2577 million. On the news front, LEADS BIOLABS-B announced that the 67th ASH Annual Meeting will be held in Orlando, Florida, USA from December 6th to 9th, 2025. The company's independently developed GPRC5D/CD3 bispecific antibody LBL-034 for the treatment of relapsed/refractory multiple myeloma ("RRMM") gave the first oral presentation on the first day of the conference. The phase I/II clinical study of LBL-034 is led by Professor Lu Jin from Peking University People's Hospital and conducted at 17 centers nationwide. The study confirmed the excellent safety and exciting anti-tumor activity of LBL-034 in RRMM patients (including the refractory subgroup with high-risk features), demonstrating the best therapeutic potential in its class. According to Frost & Sullivan data, as of November 2024, LBL-034 is the second most advanced global clinical progress targeting GPRC5D CD3 T-cell engager after Johnson & Johnson, and the first in Chinese clinical progress. In October 2024, LBL-034 received FDA orphan drug designation (ODD) for the treatment of multiple myeloma.